title: Subconjunctival latex paint from occupational injury.
abstract: BACKGROUND
  Accidental eye trauma with spray guns are rare, but potentially very serious, injuries. Although it is agreed that these injuries require immediate and vigorous therapy, the specifics of such therapy are poorly defined. With latex paint sprayer injuries to hands and extremities, resulting chemical-induced inflammation, high-pressure necrosis, ischemic necrosis, and gangrene require surgical debridement and possibly, amputation. With eye injuries, treatment is directed at preservation of vision, as there is a potential risk of visual loss.
  
  
  OBJECTIVE
  There is currently no consensus on optimal treatment of ocular spray paint injuries. Here we propose a management approach to ocular spray paint injuries with a successful outcome in the case reported.
  
  
  METHODS
  We report the first case, to our knowledge, of an industrial airless spray gun injury that resulted in subconjunctival deposition of latex paint in a soft contact lens wearer. Vision was preserved with medical management consisting of irrigation and topical corticosteroids, antibiotics and cycloplegics.
  
  
  CONCLUSIONS
  Although latex paint spray gun injuries to the eye are not encountered frequently in practice, this case shows that conservative medical management with no surgical intervention is effective for ocular injuries with preserved vision.
authors: Eye Foundation of Kansas City and Vision Research Center, Department of Ophthalmology, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
authors: Ashika
authors: A
authors: Odhav
authors: Ramya
authors: R
authors: Kollipara
authors: Savak
authors: S
authors: Teymoorian
authors: Ron K
authors: RK
authors: Lord
authors: David B
authors: DB
authors: Lyon
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D060389:Construction Industry; D003263:Contact Lenses, Hydrophilic; D003519:Cyclopentolate / Q000627:therapeutic use; D004636:Emergency Service, Hospital; D004917:Erythromycin / Q000627:therapeutic use; D005131:Eye Injuries / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008297:Male; D060051:Occupational Injuries / Q000209:etiology / Q000628:therapy*; D009883:Ophthalmic Solutions; D010150:Paint / Q000009:adverse effects*; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011312:Pressure / Q000009:adverse effects*; D007507:Therapeutic Irrigation
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D009883:Ophthalmic Solutions; D004917:Erythromycin; C009935:prednisolone acetate; D011239:Prednisolone; D003519:Cyclopentolate